aTyr Pharma, Inc. (ATYR) Misses Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts ATYR Hot Sheet
Join SI Premium – FREE
aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q3 EPS of ($0.26), $0.09 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $190 thousand versus the consensus estimate of $1.33 million.
For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Stardust Power (SDST) Tops Q2 EPS by 1c
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
